Supplementation of N-acetylcysteine as an adjuvant in treatment of newly diagnosed pulmonary tuberculosis patients: A prospective, randomized double blind, placebo controlled study Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
LATE-BREAKING ABSTRACT: COPD-associated severe pulmonary hypertension (COPDPH): results of a 16-weeks prospective multicenter, double-blind, placebo-controlled randomized clinical trial (RCT) [SPHERIC-1 (http://clinicaltrials.gov/ct2/show/NCT01441934)] investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013
Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012
Early treatment of borderline pulmonary arterial hypertension associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group, proof-of-concept study Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018
The effects of oral clarithromycin on airway inflammation in moderate to severe chronic obstructive pulmonary disease (COPD) - a double blind randomised controlled trial Source: Eur Respir J 2001; 18: Suppl. 33, 338s Year: 2001
A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol Source: ERJ Open Res, 5 (4) 00186-2019; 10.1183/23120541.00186-2019 Year: 2019
The clear evidence for pulmonary rehabilitation in chronic lung disease - a review of the most important randomised controlled trials Source: International Congress 2018 – PG14 The evolving world of pulmonary rehabilitation Year: 2018
High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial) Source: Eur Respir J, 59 (2) 2102930; 10.1183/13993003.02930-2021 Year: 2022
Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial. Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
LATE-BREAKING ABSTRACT: Treating the most diseased segments in patients with severe emphysema: 6 month results from the STEP-UP randomized controlled trial (RCT) Source: International Congress 2015 – Advances in therapeutic bronchoscopy Year: 2015
Results of a randomized, double blind trial of anti-tumor necrosis antibody for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005
Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis. Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019
Salutary effect of fructose-1,6-diphosphate in lung injury: a randomized double-blinded placebo clinical trial Source: Annual Congress 2007 - Lung recruitment Year: 2007
An investigator driven, single-centre randomised, double blind comparative study of standard vs high dose intravenous meropenem, in adult cystic fibrosis patients Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010
A randomized study of bronchoscopic blockade of the affected part of a lung as a part the complex treatment of patients with drug-resistant pulmonary tuberculosis Source: Annual Congress 2012 - Tuberculosis: invasive diagnostic and therapeutic interventions Year: 2012
Effects of case management on hospitalisation and exacerbation rate in severe, complex COPD: A randomized controlled trial Source: Annual Congress 2011 - Exacerbations and severe chronic respiratory disease: oxygen, rehabilitation, admission to hospital and palliative care Year: 2011
Effect of bosentan in patients with confirmed usual interstitial pneumonia (UIP) on surgical lung biopsy (SLB): subset analysis of the randomised, controlled BUILD 1 trial in IPF Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007
Evidence generation for the clinical impact of myCOPD in patients with mild, moderate and newly diagnosed COPD: a randomised controlled trial Source: ERJ Open Res, 6 (4) 00460-2020; 10.1183/23120541.00460-2020 Year: 2020
Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003